Literature DB >> 36248764

TP53 mutation-associated immune infiltration and a novel risk score model in HNSCC.

Weili Kong1, Yinze Han2, Hailing Gu1, Hui Yang3, Yi Zang4.   

Abstract

In HNSCC, few studies have focused on the relationship between wild-type TP53 and mutant TP53-related immunity and prognosis. Our objective was to explore how TP53 mutation regulates the immunophenotype of HNSCC and thus affects the prognosis of HNSCC. Cox and Lasso regression were used to establish a prognostic model of TP53-related immune genes, on which basis a nomogram was used to establish a clinical prediction model, and ROC curves were further used to evaluate the effectiveness of the model. The risk of death in the TP53WT group was only 0.68 times that in the TP53Mut group (HR = 0.68, CI: 0.5-0.91, P < 0.05). T cells, CD8 T cells, cytotoxic lymphocytes, B lineage, NK cells, myeloid dendritic cells, and fibroblasts were significantly different between the TP53Mut and TP53WT groups (all P < 0.05). Time - dependent ROC curves of nomogram were plotted for 1-, 3-, and 5-year survival to further verify the predictive power of the nomogram for prognosis, and the AUCs were 0.78, 0.82, and 0.83, respectively. We showed there are significant differences in the immune microenvironment associated with wild-type TP53 and mutant TP53. The immune model associated with TP53 mutation has a good prediction ability for the prognosis of HNSCC and may be of reference value for other tumors with high mutation rate of TP53. Notably, the effect of TP53 mutation on the prognosis of HNSCC could be illustrated from an immunologic perspective.
© 2022 The Authors.

Entities:  

Keywords:  Head and neck squamous cell carcinoma; Immune infiltration; Prognosis; TP53 gene

Year:  2022        PMID: 36248764      PMCID: PMC9563607          DOI: 10.1016/j.bbrep.2022.101359

Source DB:  PubMed          Journal:  Biochem Biophys Rep        ISSN: 2405-5808


  36 in total

1.  Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

Authors:  Akinori Takaoka; Sumio Hayakawa; Hideyuki Yanai; Dagmar Stoiber; Hideo Negishi; Hideaki Kikuchi; Shigeru Sasaki; Kohzoh Imai; Tsukasa Shibue; Kenya Honda; Tadatsugu Taniguchi
Journal:  Nature       Date:  2003-07-31       Impact factor: 49.962

Review 2.  Tumor-Suppressor Functions of the TP53 Pathway.

Authors:  Brandon J Aubrey; Andreas Strasser; Gemma L Kelly
Journal:  Cold Spring Harb Perspect Med       Date:  2016-05-02       Impact factor: 6.915

Review 3.  Immunotherapy for Head and Neck Cancer.

Authors:  Felix Sim; Rom Leidner; Richard Bryan Bell
Journal:  Oral Maxillofac Surg Clin North Am       Date:  2019-02       Impact factor: 2.802

4.  Global Burden of Head and Neck Cancer: Economic Consequences, Health, and the Role of Surgery.

Authors:  Rolvix H Patterson; Victoria G Fischman; Isaac Wasserman; Jennifer Siu; Mark G Shrime; Johannes J Fagan; Wayne Koch; Blake C Alkire
Journal:  Otolaryngol Head Neck Surg       Date:  2020-01-07       Impact factor: 3.497

5.  Profiling Tumor Infiltrating Immune Cells with CIBERSORT.

Authors:  Binbin Chen; Michael S Khodadoust; Chih Long Liu; Aaron M Newman; Ash A Alizadeh
Journal:  Methods Mol Biol       Date:  2018

6.  TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma.

Authors:  Wenjing Xiao; Nan Du; Taoyuan Huang; Jinan Guo; Xingkui Mo; Tao Yuan; Yong Chen; Ting Ye; Chunwei Xu; Wenxian Wang; Guoqiang Wang; Shangli Cai; Jing Chen
Journal:  EBioMedicine       Date:  2018-05-22       Impact factor: 8.143

7.  Swallowing disorders after treatment for head and neck cancer.

Authors:  Martina Pezdirec; Primoz Strojan; Irena Hocevar Boltezar
Journal:  Radiol Oncol       Date:  2019-06-01       Impact factor: 2.991

8.  A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.

Authors:  Xiangkun Wu; Daojun Lv; Chao Cai; Zhijian Zhao; Ming Wang; Wenzhe Chen; Yongda Liu
Journal:  Front Immunol       Date:  2020-12-17       Impact factor: 7.561

9.  Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.

Authors:  Michael Andreeff; Kevin R Kelly; Karen Yee; Sarit Assouline; Roger Strair; Leslie Popplewell; David Bowen; Giovanni Martinelli; Mark W Drummond; Paresh Vyas; Mark Kirschbaum; Swaminathan Padmanabhan Iyer; Vivian Ruvolo; Graciela M Nogueras González; Xuelin Huang; Gong Chen; Bradford Graves; Steven Blotner; Peter Bridge; Lori Jukofsky; Steve Middleton; Monica Reckner; Ruediger Rueger; Jianguo Zhi; Gwen Nichols; Kensuke Kojima
Journal:  Clin Cancer Res       Date:  2015-10-12       Impact factor: 12.531

Review 10.  The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis.

Authors:  Oliver M Fisher; Sarah J Lord; Dan Falkenback; Nicholas J Clemons; Guy D Eslick; Reginald V Lord
Journal:  Gut       Date:  2016-01-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.